TrialBritish journal of cancer2011

A phase II study of the histone deacetylase inhibitor vorinostat combined with tamoxifen for the treatment of patients with hormone therapy-resistant breast cancer.

P N Munster et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.